How Reckitt Built a Portfolio of Household Essentials

When you reach for Lysol to disinfect a surface, take a Mucinex for congestion, use Finish in your dishwasher, or open a pack of Durex condoms, you are interacting with the same British multinational consumer goods company. Reckitt Benckiser Group plc, known simply as Reckitt since its 2021 rebrand, owns all four of those brands alongside Dettol, Nurofen, Strepsils, Gaviscon, Clearasil, Woolite, and more than a dozen others.

Reckitt is publicly traded on the London Stock Exchange under the ticker symbol RKT and is a component of the FTSE 100 index. The company reported core net revenue growth of 5.2% for full year 2025, driven by strong performance in Emerging Markets. Reckitt employs approximately 40,000 people and operates in more than 60 countries.

This post covers how Reckitt assembled its portfolio through two decades of targeted acquisitions, what it currently owns, how it organizes its brands, and what its controversies reveal about operating in regulated consumer health markets.

The Origins: Two Victorian Companies Merge

Reckitt's corporate lineage traces to two businesses founded in England in the 19th century.

Reckitt & Sons was founded by Isaac Reckitt in Hull, England, in 1840. The company initially sold starch, black lead, and other household products. By the late 19th century, Reckitt's Bag Blue (a laundry whitening product) and Brasso (metal polish) had become household staples in the United Kingdom.

Benckiser GmbH was founded in 1823 by Johann Adam Benckiser in Pforzheim, Germany. The company began as a chemical goods manufacturer and, by the 20th century, had become a major European producer of industrial and consumer cleaning products.

The two companies merged in 1999 to form Reckitt Benckiser Group plc, creating a company with combined revenues of approximately £4 billion and a portfolio spanning cleaning, fabric care, and home hygiene. The merged entity traded on the London Stock Exchange and was headquartered in Slough, England.

The merger's driving logic was geographic complementarity: Reckitt had strong positions in the United Kingdom, Australia, and Commonwealth markets; Benckiser was strong in continental Europe, particularly in dishwasher products (Calgon, Finish). Together they created a company with meaningful scale across both Europe and international markets.

Building the Health and Hygiene Portfolio: Acquisitions 2005-2020

The defining phase of Reckitt's transformation from a general household goods company into a health and hygiene specialist came through a series of acquisitions that concentrated its portfolio around trusted brands in health, hygiene, and nutrition.

Boots Healthcare International (2006): Reckitt acquired Boots Healthcare International, the over-the-counter medicines division of Boots Group, for approximately £1.9 billion. This single acquisition brought Nurofen (ibuprofen), Strepsils (sore throat lozenges), Gaviscon (antacid), and Clearasil (acne treatment) into the portfolio, establishing Reckitt as a significant player in consumer health.

Adams Respiratory Therapeutics (2008): Reckitt acquired Adams Respiratory Therapeutics, the maker of Mucinex, for approximately $2.3 billion. Mucinex had been one of the fastest-growing consumer health brands in the United States, having grown from $0 to $300 million in revenue in its first three years after FDA approval for over-the-counter sale.

SSL International (2010): Reckitt acquired SSL International, the maker of Durex condoms and Scholl foot care products, for approximately £2.54 billion. The Durex acquisition made Reckitt the world's largest condom manufacturer and gave it a leading position in the sexual health category.

Mead Johnson Nutrition (2017): Reckitt's largest acquisition to date was Mead Johnson Nutrition, the maker of Enfamil infant formula and Enfalac nutritional products, for approximately $16.6 billion. This acquisition was intended to transform Reckitt into a major player in the infant nutrition category and diversify it beyond its household and health portfolio.

The Mead Johnson acquisition proved controversial. It significantly increased Reckitt's debt burden and the infant nutrition business underperformed expectations. The category faced regulatory scrutiny over marketing practices and faced significant product liability litigation in the United States.

In 2023, Reckitt announced the strategic review of the infant nutrition business, which trades as the Mead Johnson brand primarily in North America and China. The company has indicated its intention to separate this business, either through a sale or independent listing.

The Current Portfolio: Two Business Units

Reckitt currently organizes its portfolio into two primary business segments:

• Lysol (US): The leading disinfectant and antibacterial cleaning brand in the United States, with a product range spanning sprays, wipes, and multi-surface cleaners
• Dettol (international): The dominant antibacterial brand in the United Kingdom, India, Australia, and numerous international markets; Dettol is one of the most recognized consumer brand names in the developing world
• Finish: The leading dishwasher detergent brand in Europe, the United Kingdom, and several international markets
• Vanish: Fabric stain removal products
• Woolite: Delicate fabric laundry care
• Calgon: Washing machine maintenance tablets
• Air Wick: Air freshener and home fragrance products, competing with Glade from S.C. Johnson

• Mucinex: Over-the-counter expectorant and cold and flu relief products, primarily sold in the United States
• Nurofen: Ibuprofen-based pain and fever relief, sold across Europe, Australia, and international markets
• Strepsils: Sore throat lozenges
• Gaviscon: Antacid and acid reflux relief
• Clearasil: Acne treatment skincare (divested to Prestige Brands in 2018)
• Durex: Condoms and sexual health products
• Scholl: Foot care products

The separation of Hygiene and Health into distinct segments reflects a strategic shift toward operating the two business units with different investment profiles and potentially different ownership structures in the medium term.

Lysol and the COVID-19 Effect

The COVID-19 pandemic transformed Lysol from a significant but underinvested brand into one of the most in-demand consumer products in the world. Demand for Lysol disinfectant sprays and wipes surged in 2020 as consumers sought products to kill pathogens on surfaces, shelves emptied globally, and Reckitt significantly accelerated manufacturing investment.

The pandemic also produced one of the most unusual brand moments in Reckitt's history. In April 2020, then-US President Donald Trump suggested at a press briefing that injecting disinfectants into the body might treat COVID-19 infection. Reckitt responded within hours with an explicit public statement warning consumers under no circumstances to ingest or inject Lysol or any other disinfectant, stating the company's products were solely for external surface use. The incident required no brand reformulation but generated global attention that temporarily increased consumer awareness of Lysol beyond its typical household penetration.

Lysol revenue peaked in 2020 and has declined from those highs as COVID-19 restrictions eased and consumer cleaning behavior normalized. However, the pandemic permanently elevated consumer awareness of surface hygiene and disinfection products, and Lysol's volume remains above 2019 pre-pandemic levels.

Controversies: Legal and Regulatory History

Reckitt's history includes several significant legal and regulatory challenges that are part of the public record.

Nurofen Misleading Claims (Australia, 2016): Australia's Federal Court found Reckitt guilty of misleading and deceptive conduct for selling Nurofen range products (Nurofen Back Pain, Migraine Pain, Period Pain) at premium prices with the implication that each product targeted a specific type of pain. In fact, the products were identical formulations of ibuprofen. Reckitt was fined AUD 6 million and was required to remove the misleading products from Australian shelves.

Mead Johnson Litigation (United States, ongoing): Reckitt has faced significant product liability litigation in the United States related to Mead Johnson's Enfamil premature infant formula. Plaintiffs allege that Enfamil contributed to necrotizing enterocolitis, a serious intestinal condition in premature infants, and that Reckitt failed to adequately warn consumers of the risk. Several juries have returned verdicts in the hundreds of millions of dollars against Reckitt in individual cases, and the cumulative liability exposure is material to the company's financial position.

Suboxone Antitrust Investigation (United States): Reckitt faced regulatory scrutiny in the United States over its conduct in connection with the transition from Suboxone tablets to Suboxone film for opioid addiction treatment. The company reached settlements with state attorneys general regarding allegations that it sought to delay generic competition.

How Reckitt Competes

Reckitt operates in markets where its primary competitors are some of the world's largest consumer goods companies.

In household hygiene and cleaning, Reckitt competes against Procter & Gamble (Febreze, Tide, Mr. Clean), Unilever (Domestos, Cif), and S.C. Johnson (Windex, Pledge, Raid).

In consumer health, the competitive landscape includes Johnson & Johnson Consumer Health (now Kenvue), Bayer Consumer Health (Aleve, Claritin, Alka-Seltzer), Haleon (Advil, Sensodyne), and Pfizer Consumer Healthcare.

Reckitt's competitive differentiation rests on its brands' established consumer trust in specific categories. Lysol and Dettol occupy near-dominant positions in the household disinfectant category in their respective markets, a position built over decades of consistent positioning around germ-kill efficacy.

Frequently Asked Questions About Reckitt

Is Reckitt publicly traded? Yes. Reckitt Benckiser Group plc trades on the London Stock Exchange under ticker symbol RKT and is a component of the FTSE 100 index.

What brands does Reckitt own? Reckitt's most recognized brands include Lysol (US), Dettol (international), Mucinex, Nurofen, Strepsils, Gaviscon, Durex, Finish, Vanish, Woolite, Scholl, Calgon, and Air Wick. The company also owns Enfamil infant formula through its Mead Johnson Nutrition division, though this business is under strategic review for potential separation.

Are Lysol and Dettol the same thing? Lysol and Dettol serve similar functions as antibacterial disinfectant brands, and both are owned by Reckitt. However, they are marketed separately in different geographic markets. Lysol is the primary brand in North America; Dettol is the primary brand in the United Kingdom, India, Australia, and many international markets. Their formulations differ between product types within each brand's range.

What happened with the Reckitt Nurofen case in Australia? Australia's Federal Court ruled in 2016 that Reckitt had engaged in misleading and deceptive conduct by selling multiple Nurofen products at premium prices with pain-specific labeling (Back Pain, Migraine Pain, Period Pain), when all products were identical ibuprofen formulations. Reckitt was fined AUD 6 million and required to remove the products.

Is Reckitt involved in litigation over infant formula? Yes. Reckitt's Mead Johnson Nutrition subsidiary faces significant product liability litigation in the United States related to Enfamil premature infant formula and alleged links to necrotizing enterocolitis. The litigation represents a material legal liability for the company and is one of the factors driving the strategic review of the infant nutrition business.

Explore Related Brands

• Windex - Competing glass cleaner brand owned by S.C. Johnson
• Glade - Competing air freshener brand owned by S.C. Johnson
• Clinique - Personal care brand with overlapping health/beauty positioning
• Procter & Gamble - Primary competitor in household cleaning categories

Browse all Household Consumer Goods brands

Sources

1. Reckitt Benckiser Full Year 2025 Results — https://www.reckitt.com/investors/ 2. London Stock Exchange: RKT Company Profile — https://www.londonstockexchange.com 3. Australian Federal Court Ruling on Nurofen (2016) — https://www.judgments.fedcourt.gov.au 4. SEC EDGAR: Reckitt 20-F Filing — https://www.sec.gov/cgi-bin/browse-edgar 5. Wikidata: Reckitt Benckiser — https://www.wikidata.org/wiki/Q163541 6. Financial Times: Mead Johnson litigation coverage — https://www.ft.com

All brand ownership data verified through WhoBrands.com research. Last verified: March 2026.